Pharmaceutical Technology, Dec 2, 2008 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Dec 2, 2008
Online Exclusive
A Peak in Mass-Spectrometry Literature
By Sanjay Garg, PhD
A book about pharmaceutical analysis engages the reader with history and unexpected asides.
How Will the 2008 Election Results Affect the Preemption Debate?
By Jill Wechsler
The next president and the 111th Congress might change the extent of FDA's authority.
Special Report
Is Job Security Throwing You Off Balance?
By Maribel Rios
Results from Pharmaceutical Technology's Annual Employment Survey.
Innovations in Pharma Science
Pharmaceutical Technology is pleased to recognize the winners of its Innovations in Pharma Science Awards.
Peer-Reviewed Research
Drug Substance Starting Material Selection
By Graham T. Illing , Robert J. Timko , Linda Billett
The authors review the current regulatory framework for the selection of drug substance starting materials.
Formulation of Sustained-Release Ketorolac Tromethamine Pellets
By Mohamed Etman , Hala Nada , Aly Nada , Fatma Ismail , Mamdouh Moustafa , Said Khalil
The authors evaluated the effect of polymer composition on the drug-release profile and the effect of storage conditions on dissolution characteristics.
Ingredients Insider
Gauging Innovation in Pharmaceutical Development and Manufacturing
By Patricia Van Arnum
A recent Pharmaceutical Technology survey examined the level, sources, and reasons behind innovation in drug development and manufacturing. This article contains bonus online-exclusive material.
Washington Report
Industry Changes and Challenges
By Jill Wechsler
To expand coverage amidst the economic crisis, Obama will look for ways to cut healthcare costs.
Outsourcing Outlook
Economy Hits R&D Hardest
By Jim Miller
Early development spending has decreased sharply as industry responds to the financial crisis.
The Blame Game
By Control, a senior compliance officer
When accusations fly: 'Tis better to give than to receive.
From The Editor
A Tale of Two Pharmaceutical Industries
By Michelle Hoffman
China's quality approach to domestic versus exported products seems to be a lose-lose situation.
Report From: India
By A. Nair
While the world pulls itself out from one of the worst crises in decades, Indian pharmaceutical companies are trying to capitalize on falling company prices by increasing their takeovers.
The Good, the Bad, and the Best Jobs
Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.
PharmTech Talk
Billion-Dollar Deals of 2008
By Alexis Pellek
The past year saw major acquisitions attempted, completed, rejected, and stalled.
In the Spotlight
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here